SVB Leerink Maintains Outperform on Quanterix, Lowers Price Target to $50
SVB Leerink analyst Puneet Souda maintains Quanterix (NASDAQ:QTRX) with a Outperform and lowers the price target from $70 to $50.
Recap: Quanterix Q4 Earnings
Quanterix (NASDAQ:QTRX) reported its Q4 earnings results on Tuesday, March 1, 2022 at 08:00 AM.
Here's what investors need to know about the announcement.
Quanterix Q4 Net Loss $20.026M vs $9.821M In Same Qtr. Last Year, Sales $29.30M Beat $28.49M Estimate
Quanterix (NASDAQ:QTRX) reported quarterly sales of $29.30 million which beat the analyst consensus estimate of $28.49 million by 2.84 percent. This is a 12.13 percent increase over sales of $26.13 million the same
Quanterix Q3 Sales $26.70M Beat $24.01M Estimate
Quanterix (NASDAQ:QTRX) reported quarterly sales of $26.70 million which beat the analyst consensus estimate of $24.01 million by 11.20 percent. This is a 14.94 percent decrease over sales of $31.39 million the same
Earnings Scheduled For November 4, 2021
Companies Reporting Before The Bell
• DISH Network (NASDAQ:DISH) is likely to report quarterly earnings at $0.91 per share on revenue of $4.45 billion.
12 Health Care Stocks Moving In Tuesday’s Pre-Market Session
Gainers
Viridian Therapeutics (NASDAQ:VRDN) stock rose 22.49% to $19.17 during Tuesday's pre-market session. The company's market cap stands at $331.8 million.
